Cargando…
Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease
Parkinson’s disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962442/ https://www.ncbi.nlm.nih.gov/pubmed/35203675 http://dx.doi.org/10.3390/biomedicines10020466 |
_version_ | 1784677805712211968 |
---|---|
author | Troshev, Dmitry Voronkov, Dmitry Pavlova, Anastasia Abaimov, Denis Latanov, Alexander Fedorova, Tatiana Berezhnoy, Daniil |
author_facet | Troshev, Dmitry Voronkov, Dmitry Pavlova, Anastasia Abaimov, Denis Latanov, Alexander Fedorova, Tatiana Berezhnoy, Daniil |
author_sort | Troshev, Dmitry |
collection | PubMed |
description | Parkinson’s disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristics of the disease. One of such models, in which neuropathology is induced by chronic injections of low doses of mitochondrial toxin rotenone, is well established in rats. However, data on this model adapted to mice remain controversial. We have designed the study to describe the timecourse of motor and non-motor symptoms during chronic subcutaneous administration of rotenone (4 mg/kg daily for 35 days) in C57BL/6 mice. We characterize the underlying neuropathological processes (dopaminergic neuron degeneration, regional brain metabolism, monoamine neurotransmitter and lipid peroxidation changes) at different timepoints: 1 day, 2 weeks and 5 weeks of daily rotenone exposure. Based on the behavioral data, we can describe three stages of pathology: cognitive changes from week 2 of rotenone exposure, subtle motor changes in week 3–4 and motor dysfunction starting roughly from week 4. Neuropathological changes in this model include a general decrease in COX activity in different areas of the brain (acute effect of rotenone) and a more specific decrease in midbrain (chronic effect), followed by significant neurodegeneration in SNpc but not VTA by the 5th week of rotenone exposure. However, we were unable to find changes in the level of monoamine neurotransmitters neither in the striatum nor in the cortex, nor in the level of lipid peroxidation in the brainstem. Thus, the gradual progression of pathology in this model is linked with metabolic changes, rather than with oxidative stress or tonic neurotransmitter release levels. Overall, this study supports the idea that a low-dose rotenone mouse model can also reproduce different stages of PD as well as rats. |
format | Online Article Text |
id | pubmed-8962442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89624422022-03-30 Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease Troshev, Dmitry Voronkov, Dmitry Pavlova, Anastasia Abaimov, Denis Latanov, Alexander Fedorova, Tatiana Berezhnoy, Daniil Biomedicines Article Parkinson’s disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristics of the disease. One of such models, in which neuropathology is induced by chronic injections of low doses of mitochondrial toxin rotenone, is well established in rats. However, data on this model adapted to mice remain controversial. We have designed the study to describe the timecourse of motor and non-motor symptoms during chronic subcutaneous administration of rotenone (4 mg/kg daily for 35 days) in C57BL/6 mice. We characterize the underlying neuropathological processes (dopaminergic neuron degeneration, regional brain metabolism, monoamine neurotransmitter and lipid peroxidation changes) at different timepoints: 1 day, 2 weeks and 5 weeks of daily rotenone exposure. Based on the behavioral data, we can describe three stages of pathology: cognitive changes from week 2 of rotenone exposure, subtle motor changes in week 3–4 and motor dysfunction starting roughly from week 4. Neuropathological changes in this model include a general decrease in COX activity in different areas of the brain (acute effect of rotenone) and a more specific decrease in midbrain (chronic effect), followed by significant neurodegeneration in SNpc but not VTA by the 5th week of rotenone exposure. However, we were unable to find changes in the level of monoamine neurotransmitters neither in the striatum nor in the cortex, nor in the level of lipid peroxidation in the brainstem. Thus, the gradual progression of pathology in this model is linked with metabolic changes, rather than with oxidative stress or tonic neurotransmitter release levels. Overall, this study supports the idea that a low-dose rotenone mouse model can also reproduce different stages of PD as well as rats. MDPI 2022-02-16 /pmc/articles/PMC8962442/ /pubmed/35203675 http://dx.doi.org/10.3390/biomedicines10020466 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Troshev, Dmitry Voronkov, Dmitry Pavlova, Anastasia Abaimov, Denis Latanov, Alexander Fedorova, Tatiana Berezhnoy, Daniil Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease |
title | Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease |
title_full | Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease |
title_fullStr | Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease |
title_full_unstemmed | Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease |
title_short | Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease |
title_sort | time course of neurobehavioral disruptions and regional brain metabolism changes in the rotenone mice model of parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962442/ https://www.ncbi.nlm.nih.gov/pubmed/35203675 http://dx.doi.org/10.3390/biomedicines10020466 |
work_keys_str_mv | AT troshevdmitry timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease AT voronkovdmitry timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease AT pavlovaanastasia timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease AT abaimovdenis timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease AT latanovalexander timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease AT fedorovatatiana timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease AT berezhnoydaniil timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease |